TransCode Therapeutics Inc
RNAZ
TransCode Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue TTM with 2.8M cash vs 14.5M annual burn - under 3 months runway without new financing[Cash and Equivalents]
- R&D spend of 11.6M TTM is 72% of operating expenses - pure clinical-stage biotech with no commercial ops[Research and Development TTM]
- Market cap of 7.9M with EV of 5.1M implies market pricing near-term dilution or failure[Market Cap TTM]
Watch Triggers
- Cash and Equivalents: Falls below 1.5M or new financing announced — Sub-1.5M triggers going concern; financing terms dictate dilution severity
- Issuance of Capital Stock: Any non-zero value in next quarter — Terms of raise (price, warrants) determine if equity holders survive
- Research and Development TTM: Drops below 8M quarterly run-rate — R&D cuts signal pipeline abandonment vs cash preservation
Bull Case
Micro-cap (7.9M) with zero debt - any positive clinical news or partnership could generate outsized returns from depressed base
R&D-focused (72% of opex) with tangible book of 1.4M - trading at 5.6x book despite no debt overhang
Bear Case
Cash runway under 3 months at current burn - imminent dilution or bankruptcy risk with zero revenue
EPS of -223.93 TTM with ROE of -1763% - destroying equity faster than raising it
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage RNAZ's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary outcome: either raises capital within 6 months or faces operational shutdown
- Cash burn of 14.5M TTM vs 2.8M cash
- Zero debt capacity with 1.4M equity
- No revenue pathway near-term
Public Strategies Rankings
See how TransCode Therapeutics Inc ranks across different investment strategies.
Leverage RNAZ's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
RNAZ Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$7.57M | — | ||
$4.73M | — | ||
0.00 | — | ||
$0 | — | ||
$-223.93 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-14.52M | — | ||
-18 | -1273.0% | — | |
Beta 5Y (Monthly) | unknown | — |
RNAZ Dividend History
RNAZ Stock Splits
RNAZ SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/14/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/14/25 | 03/31/25 | 10-Q | |
04/15/25 | 12/31/24 | 10-K | |
11/14/24 | 09/30/24 | 10-Q | |
08/14/24 | 06/30/24 | 10-Q | |
05/15/24 | 03/31/24 | 10-Q | |
04/01/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/15/23 | 03/31/23 | 10-Q | |
03/31/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/15/22 | 06/30/22 | 10-Q | |
05/16/22 | 03/31/22 | 10-Q | |
03/31/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/23/21 | 06/30/21 | 10-Q | |
07/09/21 | 03/31/21 | 424B4 | |
07/09/21 | 12/31/20 | 424B4 | |
11/15/21 | 09/30/20 | 10-Q | |
08/23/21 | 06/30/20 | 10-Q | |
07/09/21 | 03/31/20 | 424B4 |